专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018039475A8 USE OF PRIDOPIDINE FOR TREATING DYSTONIAS 审中-公开
公开(公告)号：WO2018039475A8
公开(公告)日：2018-03-01
申请号：PCT/US2017/048458
申请日：2017-08-24
申请人： TEVA PHARMACEUTICALS INTERNATIONAL GMBH , HAYDEN, Michael , PAPAPETROPOULOS, Spyridon , SAVOLA, Juha-MATTI , EYAL, Eli , BOROWSKY, Beth , GRACHEV, Igor, D. , GORDON, Mark, Forrest
发明人： HAYDEN, Michael , PAPAPETROPOULOS, Spyridon , SAVOLA, Juha-MATTI , EYAL, Eli , BOROWSKY, Beth , GRACHEV, Igor, D. , GORDON, Mark, Forrest
IPC分类号： A61K31/451
摘要： The invention provides a method of treating a subject afflicted with a dystonia, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.

2. 发明申请

WO2007067617A3 USE OF A CB1 ANTAGONIST FOR TREATING NEGATIVE SYMPTOMS OF SCHIZOPHRENIA 审中-公开
标题翻译：使用CB1拮抗剂治疗嗜酸性粒细胞减少症状
公开(公告)号：WO2007067617A3
公开(公告)日：2007-11-01
申请号：PCT/US2006046547
申请日：2006-12-07
申请人： AVENTIS PHARMA INC , BLACK MARK , BOROWSKY BETH , ROGACKI NANCY , SENYAH YAW , STEVENS RACHEL
发明人： BLACK MARK , BOROWSKY BETH , ROGACKI NANCY , SENYAH YAW , STEVENS RACHEL
IPC分类号： A61K31/397 , A61K31/445 , A61K31/519 , A61P25/18
CPC分类号： A61K31/445 , A61K31/397 , A61K31/519
摘要： The present invention discloses and claims a method of treating cognition deficits in a patient suffering from schizophrenia by administering to said patient a therapeutically effective amount of a CBl receptor antagonist as described herein. In another aspect, this invention also discloses and claims a combination of one or more CBl receptor antagonists and of one or more antipsychotic agents useful in the treatment of psychiatric disorders . The combination of this invention provides beneficial results in that the combination improves positive and negative symptoms of schizophrenia, while reducing weight gain and catalepsy induced by antipsychotic drugs .
摘要翻译：本发明公开并要求通过向所述患者施用治疗有效量的本文所述的CB1受体拮抗剂来治疗患有精神分裂症患者的认知缺陷的方法。在另一方面，本发明还公开并要求保护一种或多种CB1受体拮抗剂和一种或多种抗精神病药物用于治疗精神疾病的组合。本发明的组合提供了有益的结果，其中组合改善精神分裂症的正和负面症状，同时降低由抗精神病药物引起的体重增加和僵住症。

3. 发明申请

WO1998015570A1 DNA ENCODING GALANIN GALR3 RECEPTORS AND USES THEREOF 审中-公开
标题翻译： DNA编码GALANIN GALR3受体及其用途
公开(公告)号：WO1998015570A1
公开(公告)日：1998-04-16
申请号：PCT/US1997018222
申请日：1997-10-09
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION , BARD, Jonathan, A. , BOROWSKY, Beth , SMITH, Kelli, E. , BRANCHEK, Theresa, A. , GERALD, Christophe, P., G. , JONES, Kenneth, A.
发明人： SYNAPTIC PHARMACEUTICAL CORPORATION
IPC分类号： C07K01/14
CPC分类号： C07K16/2869 , A01K2217/05 , A61K38/00 , C07K14/72 , G01N33/5088 , G01N33/74 , G01N2333/72 , G01N2500/10
摘要： This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.
摘要翻译：本发明提供编码哺乳动物甘丙肽受体的分离的核酸，分离的甘丙肽受体蛋白，包含编码哺乳动物甘丙肽受体的分离的核酸的载体，包含该载体的细胞，针对哺乳动物甘丙肽受体的抗体，用于检测核酸的核酸探针编码哺乳动物甘丙肽受体的酸，与编码哺乳动物甘丙肽受体的核酸的独特序列互补的反义寡核苷酸，表达编码正常或突变型哺乳动物甘丙肽受体的DNA的非人转基因动物，以及确定化合物与哺乳动物甘丙肽的结合的方法受体。

4. 发明申请

WO03003983A3 RECEPTOR AGONISTS USEFUL FOR THE TREATMENT OF PAIN 审中-公开
标题翻译：用于治疗疼痛的受体激素
公开(公告)号：WO03003983A3
公开(公告)日：2003-09-04
申请号：PCT/US0221103
申请日：2002-07-02
申请人： SYNAPTIC PHARMA CORP , BOROWSKY BETH E , QUAN YONG , SMITH KELLI E
发明人： BOROWSKY BETH E , QUAN YONG , SMITH KELLI E
IPC分类号： C07K14/705 , A61K38/00 , A61K38/18 , A61K45/00
CPC分类号： C07K14/70567
摘要： This invention provides a method of treating a subject suffering from an abnormality which comprises administering to the subject an amount of a SNORF11 receptor agonist effective to treat the subject's abnormality. This invention further provides a method of treating pain, particularly chronic pain, chronic inflammatory pain and arthritic pain, which comprises administering to the subject an amount of a SNORF11 receptor agonist effective to treat the subject's pain.
摘要翻译：本发明提供了治疗患有异常的受试者的方法，其包括向受试者施用一定量的有效治疗受试者异常的SNORF11受体激动剂。本发明还提供了治疗疼痛，特别是慢性疼痛，慢性炎性疼痛和关节炎疼痛的方法，其包括向受试者施用一定量的有效治疗受试者的疼痛的SNORF11受体激动剂。

5. 发明申请

WO2005097122A2 METHOD OF TREATING SCHIZOPHRENIA AND/OR GLUCOREGULATORY ABNORMALITIES 审中-公开
标题翻译：治疗嗜酸性粒细胞减少症和/或葡萄糖不育症的方法
公开(公告)号：WO2005097122A2
公开(公告)日：2005-10-20
申请号：PCT/US2005/011107
申请日：2005-04-01
申请人： AVENTIS PHARMACEUTICALS INC. , SMITH, Craig, P. , RAMPE, David, E. , BOROWSKY, Beth , KONGSAMUT, Sathapana
发明人： SMITH, Craig, P. , RAMPE, David, E. , BOROWSKY, Beth , KONGSAMUT, Sathapana
IPC分类号： A61K31/4439
CPC分类号： A61K31/4439
摘要： The present invention provides methods of treating schizophrenia and/or glucoregulatory abnormalities in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of formula (I) wherein m is 0, 1 or 2; n is 0, 1 or 2; p is 0 or 1; each R is independently hydrogen, halogen, trifluoromethyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, benzyloxy, hydroxy, nitro or amino; each R 1 is independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkenyl, C 1 -C 6 alkanoyl, halogen, cyano, -C(O) C 1 -C 6 alkyl, -C 1 -C 6 alkyleneCN, -C 1 -C 6 alkyleneNR’R” wherein R’ and R” are each independently hydrogen or C 1 -C 6 alkyl, -C 1 -C 6 alkyleneOC(O)C 1 -C 6 alkyl, or -CH(OH)R 4 wherein R 4 is hydrogen or C 1 -C 6 alkyl; R 2 is hydrogen, C 1 -C 6 alkyl optionally substituted with halogen, hydroxy or benzyloxy, C 1 -C 6 alkenyl, C 1 -C 6 alkynyl, -CO 2 C 1 -C 6 alkyl, or -R 5 -NR’R” wherein R 5 is C 1 -C 6 alkylene, C 1 -C 6 alkenylene or C 1 -C 6 alkynylene and R’ and R” are each independently hydrogen, C 1 -C 6 alkyl or alternatively the group -NR’R” as a whole is 1-pyrrolidinyl; and R 3 is hydrogen, nitro, amino, halogen, C 1 -C 6 alkoxy, hydroxy or C 1 -C 6 alkyl or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明提供在有需要的患者中治疗精神分裂症和/或葡萄糖调节异常的方法，包括向所述患者施用治疗有效量的式（I）化合物，其中m为0,1或2; n为0,1或2; p为0或1; 每个R独立地是氢，卤素，三氟甲基，C 1 -C 6烷基，C 1 -C 6烷氧基，苄氧基，羟基，硝基或氨基; 每个R 1独立地是氢，C 1 -C 6烷基，C 1 -C 6烯基，C 1 -C 6烷酰基，卤素，氰基，-C（O）C 1 -C 6烷基，-C 1 -C 6亚烷基基团，-C 1 -C 6亚烷基NR'R“，其中R'和R” 各自独立地是氢或C 1 -C 6烷基，-C 1 -C 6亚烷基OC（O）C 1 -C 6烷基或-CH（OH）R 4，其中R 4是氢或C 1 -C 6烷基; R 2是氢，任选地被卤素，羟基或苄氧基取代的C 1 -C 6烷基，C 1 -C 6烯基，C 1 -C 6炔基，-CO 2 C 1 -C 6烷基或-R 5 -NR'R“，其中R 5是C 1 -C 6亚烷基， C 6亚炔基和R'和R“各自独立地为氢，C 1 -C 6烷基或者基团-NR'R”整体上为1-吡咯烷基; R 3为氢，硝基，氨基，卤素，C 1 -C 6烷氧基，羟基或C 1 -C 1-6烷基或其药学上可接受的盐。

6. 发明申请

WO2003003983A2 RECEPTOR AGONISTS USEFUL FOR THE TREATMENT OF PAIN 审中-公开
标题翻译：受体激动剂可用于治疗疼痛
公开(公告)号：WO2003003983A2
公开(公告)日：2003-01-16
申请号：PCT/US2002/021103
申请日：2002-07-02
申请人： SYNAPTIC PHARMACEUTICAL CORPORATION , BOROWSKY, Beth, E. , QUAN, Yong , SMITH, Kelli, E.
发明人： BOROWSKY, Beth, E. , QUAN, Yong , SMITH, Kelli, E.
IPC分类号： A61K
CPC分类号： C07K14/70567
摘要： This invention provides a method of treating a subject suffering from an abnormality which comprises administering to the subject an amount of a SNORF11 receptor agonist effective to treat the subject's abnormality. This invention further provides a method of treating pain, particularly chronic pain, chronic inflammatory pain and arthritic pain, which comprises administering to the subject an amount of a SNORF11 receptor agonist effective to treat the subject's pain.
摘要翻译：本发明提供了治疗患有异常的受试者的方法，该方法包括给受试者施用有效治疗受试者异常的量的SNORF11受体激动剂。本发明进一步提供了治疗疼痛，尤其是慢性疼痛，慢性炎性疼痛和关节炎疼痛的方法，其包括向所述对象施用有效治疗所述对象疼痛的量的SNORF11受体激动剂。

7. 发明申请

WO2018039477A1 USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE 审中-公开
标题翻译：使用PRIDOPIDINE治疗功能衰退
公开(公告)号：WO2018039477A1
公开(公告)日：2018-03-01
申请号：PCT/US2017/048461
申请日：2017-08-24
申请人： TEVA PHARMACEUTICALS INTERNATIONAL GMBH , HAYDEN, Michael , PAPAPETROPOULOS, Spyridon , SAVOLA, Juha-Matti , EYAL, Eli , BOROWSKY, Beth , GRACHEV, Igor, D.
发明人： HAYDEN, Michael , PAPAPETROPOULOS, Spyridon , SAVOLA, Juha-Matti , EYAL, Eli , BOROWSKY, Beth , GRACHEV, Igor, D.
IPC分类号： C07D211/42 , A61K31/451
摘要： This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90-225 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.
摘要翻译：本发明提供了维持人类患者的功能能力，改善功能能力或减少功能能力下降的方法，包括定期对患者口服给予包含普利多匹定的药物组合物，使得剂量每天向患者施用90-225mg普利多匹定，从而维持功能能力，改善功能能力或减轻患者功能能力的下降。

8. 发明申请

WO2018039475A1 USE OF PRIDOPIDINE FOR TREATING DYSTONIAS 审中-公开
标题翻译：用普罗布丁治疗DYSTONIAS
公开(公告)号：WO2018039475A1
公开(公告)日：2018-03-01
申请号：PCT/US2017/048458
申请日：2017-08-24
申请人： TEVA PHARMACEUTICALS INTERNATIONAL GMBH , HAYDEN, Michael , PAPAPETROPOULOS, Spyridon , SAVOLA, Juha-MATTI , EYAL, Eli , BOROWSKY, Beth , GRACHEV, Igor, D. , GORDON, Mark, Forrest
发明人： HAYDEN, Michael , PAPAPETROPOULOS, Spyridon , SAVOLA, Juha-MATTI , EYAL, Eli , BOROWSKY, Beth , GRACHEV, Igor, D. , GORDON, Mark, Forrest
IPC分类号： A61K31/451
摘要： The invention provides a method of treating a subject afflicted with a dystonia, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.
摘要翻译：本发明提供了一种治疗患有肌张力障碍的受试者的方法，所述方法包括周期性给予所述受试者包含有效治疗所述受试者的量的普利多匹定的药物组合物。

9. 发明申请

WO2007067617A2 USE OF A CB1 ANTAGONIST FOR TREATING SIDE EFFECTS AND NEGATIVE SYMPTOMS OF SCHIZOPHRENIA 审中-公开
标题翻译：使用CB1拮抗剂治疗化疗药物的副作用和不良反应症状
公开(公告)号：WO2007067617A2
公开(公告)日：2007-06-14
申请号：PCT/US2006/046547
申请日：2006-12-07
申请人： AVENTIS PHARMACEUTICALS INC. , BLACK, Mark , BOROWSKY, Beth , ROGACKI, Nancy , SENYAH, Yaw , STEVENS, Rachel
发明人： BLACK, Mark , BOROWSKY, Beth , ROGACKI, Nancy , SENYAH, Yaw , STEVENS, Rachel
CPC分类号： A61K31/445 , A61K31/397 , A61K31/519
摘要： The present invention discloses and claims a method of treating cognition deficits in a patient suffering from schizophrenia by administering to said patient a therapeutically effective amount of a CB1 receptor antagonist as described herein. In another aspect, this invention also discloses and claims a combination of one or more CB1 receptor antagonists and of one or more antipsychotic agents useful in the treatment of psychiatric disorders. The combination of this invention provides synergistic results in that the combination improves positive and negative symptoms of schizophrenia, weight gain and catalepsy.
摘要翻译：本发明公开并要求通过向所述患者施用治疗有效量的本文所述的CB1受体拮抗剂来治疗患有精神分裂症患者的认知缺陷的方法。另一方面，本发明还公开并要求保护一种或多种CB1受体拮抗剂和一种或多种抗精神病药物用于治疗精神疾病的组合。本发明的组合提供协同效果，因为该组合改善精神分裂症的积极和消极症状，体重增加和僵硬症。

10. 发明申请

WO2005097122A3 METHOD OF TREATING SCHIZOPHRENIA AND/OR GLUCOREGULATORY ABNORMALITIES 审中-公开
标题翻译：治疗嗜酸性粒细胞减少症和/或葡萄糖不育症的方法
公开(公告)号：WO2005097122A3
公开(公告)日：2006-02-02
申请号：PCT/US2005011107
申请日：2005-04-01
申请人： AVENTIS PHARMA INC , SMITH CRAIG P , RAMPE DAVID E , BOROWSKY BETH , KONGSAMUT SATHAPANA
发明人： SMITH CRAIG P , RAMPE DAVID E , BOROWSKY BETH , KONGSAMUT SATHAPANA
IPC分类号： A61K31/4439 , A61P3/10 , A61P25/18
CPC分类号： A61K31/4439
摘要： The present invention provides methods of treating schizophrenia and/or glucoregulatory abnormalities in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of formula (I) wherein m is 0, 1 or 2; n is 0, 1 or 2; p is 0 or 1; each R is independently hydrogen, halogen, trifluoromethyl, C
摘要翻译：本发明提供在有需要的患者中治疗精神分裂症和/或葡萄糖调节异常的方法，包括向所述患者施用治疗有效量的式（I）化合物，其中m为0,1或2; n为0,1或2; p为0或1; 每个R独立地为氢，卤素，三氟甲基，C

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式